Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals: Reuters
Specialty pharmaceuticals company Pozen Inc said it would acquire Tribute Pharmaceuticals Canada Inc for about US$144 million, in a deal that would shift its domicile to Ireland and cut its tax bill. The merged company, to be called Aralez Pharmaceuticals Plc, will focus on cardiovascular treatments. As part of the transaction, a group of investors, including U.S. healthcare investment firm Deerfield Management and Canadian biotech company QLT Inc, will invest up to US$350 million in growth capital for Aralez.
10 June 2015•3 mins read
